OnCusp Therapeutics
PrivateLast Round
Series A
Jan 4, 2024
Total Funding Raised
$139M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
OnCusp Therapeutics operates in Healthcare & Life Sciences and is based in Princeton, New Jersey. Its latest recorded funding round was a Series A round in January 2024.
OnCusp Therapeutics is an oncology company that develops innovative, first-in-class cancer therapies by translating preclinical research into clinical treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OnCusp Therapeutics Comparables
Compare OnCusp Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Multitude Therapeutics | 85% | |
| Phrontline Biopharma | 81% | |
| Adcendo | 78% |
For institutional investors. Book with your work email.
OnCusp Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 4, 2024 | ||||
| Seed | Aug 1, 2022 | ||||
| Seed | Apr 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
OnCusp Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series A, Seed |
| F-Prime Capital | Series A |
| OrbiMed | Series A |
| Catalio Capital Management | Series A |
| Forge Life Science Partners | Series A |
| Novo Holdings | Series A |
| F-Prime Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 39% MoM, reaching 2.2K.
- Jun 23, 2025
Dimitry S.A. Nuyten appointed as the new Chief Medical Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 5, 2026
OnCusp Therapeutics Inc attends the IGCS 2026 Annual Global Meeting in Canada, where its CUSP06 Phase 1b data are presented at a plenary oral session on Oct 3rd '26.
For institutional investors. Book with your work email.
OnCusp Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about OnCusp Therapeutics's valuation, stock price, and market status.
Is OnCusp Therapeutics a public or private company?
OnCusp Therapeutics is a private company.
What is the current stock price of OnCusp Therapeutics?
OnCusp Therapeutics is a private company, so its shares have no public market price. Caplight tracks OnCusp Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is OnCusp Therapeutics worth (valuation)?
Valuation information for OnCusp Therapeutics is not publicly available.
Can I buy OnCusp Therapeutics stock?
OnCusp Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was OnCusp Therapeutics's last funding round?
OnCusp Therapeutics's most recent funding round was Series A on January 4, 2024.
Who are the main investors in OnCusp Therapeutics?
Key investors in OnCusp Therapeutics include BioTrack Capital, F-Prime Capital, OrbiMed, Novo Holdings, F-Prime Capital.
Will OnCusp Therapeutics IPO soon?
No public IPO plans have been announced for OnCusp Therapeutics.
How can I track OnCusp Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in OnCusp Therapeutics's shares on secondary markets.